Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$11.19 - $18.56 $195,825 - $324,800
-17,500 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$16.05 - $16.87 $280,875 - $295,225
17,500 New
17,500 $295,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Blue Crest Capital Management LTD Portfolio

Follow Blue Crest Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Blue Crest Capital Management LTD with notifications on news.